Genentech: CAPSTONE-2 trial with Baloxavir Marboxil for Flu Meets primary target

Genentech: CAPSTONE-2 trial with Baloxavir Marboxil for Flu Meets primary target

  1. Genentech: CAPSTONE-2 trial with Baloxavir Marboxil for Flu Meets primary target Nasdaq
  2. Roche wins test victory for the antiviral anti-virus drug Reuters
  3. Full coverage

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.